PRAME mRNA Vaccine mRNA-4203

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer vaccine consisting of a lipid nanoparticle (LNP) encapsulating messenger RNA (mRNA) encoding for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of PRAME mRNA vaccine mRNA-4203, the LNP binds to the plasma membrane of cells, and the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed PRAME epitope is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.

**Synonyms:** - LNP-encapsulated PRAME mRNA Vaccine mRNA-4203 - mRNA 4203 - mRNA-4203 - mRNA4203